GAITHERSBURG, Md., May 08, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2018 before the market open and host a conference call on Wednesday, May 16.
Conference Call Details
Date: Wednesday, May 16
Time: 8:30am Eastern Time
Domestic: 888-394-8218
International: 323-701-0225
Conference ID: 1336227
Webcast: http://public.viavid.com/index.php?id=129546
Replays, Available through May 30th:
Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 1336227
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
enright@altimmune.com
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com